GLP-1 Drugs Like Ozempic Show Promise in Reducing Cravings for Alcohol and Cocaine

Emerging research highlights potential new uses for semaglutide, including treating substance use disorders alongside obesity and diabetes.

A randomized controlled trial found that semaglutide, the active ingredient in Ozempic and Wegovy, significantly reduced alcohol cravings and consumption in people with alcohol use disorder.
A case study documented a 54-year-old man with cocaine use disorder and obesity experiencing a 59% reduction in cocaine cravings after a 12-week semaglutide treatment.
Participants in a clinical trial reported a 30% reduction in drinks per drinking day and fewer heavy drinking episodes compared to a placebo group.
Researchers believe GLP-1 drugs may act on brain receptors to regulate responses to addictive stimuli, though the exact mechanisms remain unclear.
Preliminary findings suggest semaglutide could address substance use disorders, but larger and longer studies are needed to confirm its safety and efficacy.